## Lam Research Corporation Reports Financial Results for the Quarter Ended December 28, 2014

 2014 quarter").

Highlights for the December 2014 quarter were as follows:

- Shipments of $\$ 1,247$ million, up $12 \%$ from the prior quarter
- Revenue of $\$ 1,232$ million, up $7 \%$ from the prior quarter.
- GAAP gross margin of $43.6 \%$, GAAP operating margin of $15.3 \%$ and GAAP diluted EPS of $\$ 1.00$
- Non-GAAP gross margin of $45.4 \%$, non-GAAP operating margin of $18.7 \%$, and non-GAAP diluted EPS of $\$ 1.19$


## Lam Research Corporation

Financial Highlights for the Quarters Ended December 28, 2014 and September 28, 2014
(in thousands, except per share data and percentages)

| GAAP |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | December 2014 |  | September 2014 | Change Q/Q |
| Revenue | \$ | 1,232,241 | \$ | 1,152,368 | 7\% |
| Gross margin as percentage of revenue |  | 43.6\% |  | 43.9\% | -30 bps |
| Operating margin as percentage of revenue |  | 15.3\% |  | 14.6\% | 70 bps |
| Diluted EPS | \$ | 1.00 | \$ | 0.80 | 25\% |
| Non-GAAP |  |  |  |  |  |
|  |  | December 2014 |  | September 2014 | Change Q/Q |
| Revenue | \$ | 1,232,241 | \$ | 1,152,368 | 7\% |
| Gross margin as percentage of revenue |  | 45.4\% |  | 45.8\% | -40 bps |
| Operating margin as percentage of revenue |  | 18.7\% |  | 18.0\% | 70 bps |
| Diluted EPS | \$ | 1.19 | \$ | 0.96 | 24\% |

## GAAP Financial Results



 ended September 28, 2014 (the "September 2014 quarter").

## Non-GAAP Financial Results


 non-GAAP operating expenses of $\$ 321.2$ million, non-GAAP operating margin of $18.0 \%$ of revenue, and non-GAAP net income of $\$ 167.7$ million, or $\$ 0.96$ per diluted share for the September 2014 quarter.
"Lam's December quarter concludes a record calendar year for the Company defined by outperformance in our industry and strong execution on our priorities," said Martin Anstice, Lam Research's president and chief executive officer. "For the year we grew revenue at twice the rate of the industry and made good progress on our market share objectives. Our strong execution combined with a meaningful market expansion is enabling a compelling multi-year growth opportunity."
Balance Sheet and Cash Flow Results

 employee stock-based compensation, $\$ 61.4$ million of capital expenditures and $\$ 29.4$ million of cash dividends paid to stockholders during the December 2014 quarter


 the time of acceptance. The anticipated future revenue from shipments to Japanese customers was approximately $\$ 53.2$ million as of December 28,2014 .

Geographic Distribution
The geographic distribution of shipments and revenue during the December 2014 quarter is shown in the following table:

| Region | Shipments | Revenue |
| :--- | :--- | :--- |
| Taiwan | $23 \%$ | $25 \%$ |
| Korea | $30 \%$ | $24 \%$ |
| United States | $16 \%$ | $18 \%$ |
| Japan | $13 \%$ | $12 \%$ |
| China | $7 \%$ | $8 \%$ |
| Southeast Asia | $4 \%$ | $7 \%$ |
| Europe | $7 \%$ | $6 \%$ |

Outlook
For the quarter ending March 29, 2015, Lam is providing the following guidance:

|  | GAAP |  |  | Reconciling Items | Non-GAAP |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Shipments | \$1.45 Billion | +/- | \$50 Million | - | \$1.45 Billion | +/- | \$50 Million |
| Revenue | \$1.37 Billion | +/- | \$50 Million | - | \$1.37 Billion | +/- | \$50 Million |
| Gross margin | 42.5\% | +/- | 1\% | \$21 Million | 44.0\% | +/- | 1\% |
| Operating margin | 16.3\% | +/- | 1\% | \$37 Million | 19.0\% | +/- | 1\% |
| Earnings per share | \$1.06 | +/- | \$0.07 | \$38 Million | \$1.30 | +/- | \$0.07 |
| Diluted share count | 177 Million |  |  | 3 Million | 174 Million |  |  |



 model and the variations may be material. Reconciling items included above are as follows:

- Gross margin -- amortization related to intangible assets acquired in the Novellus transaction, $\$ 21$ million.
- Operating margin -- amortization related to intangible assets acquired in the Novellus transaction, $\$ 37$ million.
- Earnings per share -- amortization related to intangible assets acquired in the Novellus transaction, $\$ 37$ million; amortization of convertible note discounts, $\$ 8$ million; and associated tax benefit for non-GAAP items ( $\$ 7$ ) million; totaling $\$ 38$ million.
- Diluted share count -- impact of a note hedge issued contemporaneously with the convertible notes due in 2016 and 2018 , 3 million shares.


## Use of Non-GAAP Financial Results

In addition to GAAP results, this press release also contains non-GAAP financial results. The Company's non-GAAP results for both the December 2014 and September 2014 quarters include the impact of the note hedge issued contemporaneously with the convertible notes due in 2016 and 2018 and exclude amortization related to intangible assets acquired in the Novellus transaction, the amortization of convertible note discounts, and tax expense (benefit) of non-GAAP items. Additionally, the December 2014 quarter non-GAAP results exclude acquisition-related inventory fair value adjustments, cost of restructuring and tax benefit on reinstatement of research and development credit. The September 2014 quarter non-GAAP results also exclude the rationalization of certain product configurations, gain associated with disposition of a business, and tax benefit on valuation allowance adjustment.

Management uses non-GAAP gross margin, operating income, operating expenses, operating margin, net income, and net income per diluted share to evaluate the Company's operating and financial results. The Company believes the presentation of non-GAAP results is useful to investors for analyzing business trends and comparing performance to prior periods, along with enhancing investors' ability to view the Company's results from management's perspective. Tables presenting reconciliations of non-GAAP results to GAAP results are included at the end of this press release and on the Company's web site at http://investor.lamresearch.com.

Caution Regarding Forward-Looking Statements
Statements made in this press release that are not of historical fact are forward-looking statements and are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to, but are not limited to, the anticipated revenue from shipments to Japanese customers; our ability to continue to outperform the semiconductor equipment industry; our ability to continue to grow our revenue and make progress on our market share objectives; our ability to execute and deliver performance that meets or exceeds our plans, including our abilities to execute on our priorities, and deliver multi-year growth; the scope of opportunities we have; our ability to expand our served market; the ability of the market to continue to expand and the extent of any such expansion; and our guidance for shipments, revenue, gross margin, operating margin, earnings per share, and diluted share count. Some factors that may affect these forward-looking statements include: business conditions in the consumer electronics industry, the semiconductor industry and the overall economy; the strength of the financial performance of our existing and prospective customers; the introduction of new and innovative technologies; the occurrence and pace of technology transitions and conversions; the actions of our competitors, consumers, semiconductor companies and key suppliers and subcontractors; and the success of research and development and sales and marketing programs. These forward-looking statements are based on current expectations and are subject to uncertainties and changes in condition, significance, value and effect as well as other risks, including those detailed in documents filed by us with the Securities and Exchange Commission, including specifically our report on Form 10-K for the year ended June 29, 2014 and the Form 10-Q for the quarter ended September 28, 2014. These uncertainties and changes could cause actual results to vary from expectations. The Company undertakes no obligation to update the information or statements made in this press release.

About Lam Research
Lam Research Corp.(NASDAQ: LRCX) is a trusted global supplier of innovative wafer fabrication equipment and services to the semiconductor industry. Lam's broad portfolio of market-leading deposition, etch, strip, and wafer cleaning solutions helps customers achieve success on the wafer by enabling device features that are 1,000 times smaller than a grain of sand, resulting in smaller, faster, and more power-efficient chips. Through collaboration, continuous innovation, and delivering on commitments, Lam is transforming atomic-scale engineering and enabling its customers to shape the future of technology. Based in Fremont, Calif., Lam Research is a NASDAQ-100 Index® and S\&P $500 ®$ company whose common stock trades on the NASDAQ® Global Select Market ${ }^{\text {m }}$ under the symbol LRCX. For more information, please visit http://www.lamresearch.com. (LRCX-F)
Consolidated Financial Tables Follow.

LAM RESEARCH CORPORATION

## CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data and percentages)
(unaudited)

|  | Three Months Ended |  |  |  |  |  |  |  | Six Months Ended |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | December$28,2014$ |  | September$28,2014$ |  |  | December <br> 29, 2013 |  |  | December$\text { 28, } 2014$ |  |  | $\begin{aligned} & \text { December } \\ & 29,2013 \end{aligned}$ |  |
| Revenue | \$ | 1,232,241 | \$ | 1,152,368 |  | \$ | 1,116,061 |  | \$ | 2,384,609 |  | \$ | 2,131,120 |
| Cost of goods sold |  | 695,584 |  | 646,829 |  |  | 628,272 |  |  | 1,342,413 |  |  | 1,211,473 |
| Gross margin |  | 536,657 |  | 505,539 |  |  | 487,789 |  |  | 1,042,196 |  |  | 919,647 |
| Gross margin as a percent of revenue |  | 43.6\% |  | 43.9\% |  |  | 43.7\% |  |  | 43.7\% |  |  | 43.2\% |
| Research and development |  | 196,768 |  | 188,934 |  |  | 174,477 |  |  | 385,702 |  |  | 345,044 |
| Selling, general and administrative |  | 151,148 |  | 148,307 |  |  | 148,838 |  |  | 299,455 |  |  | 304,721 |
| Total operating expenses |  | 347,916 |  | 337,241 |  |  | 323,315 |  |  | 685,157 |  |  | 649,765 |
| Operating income |  | 188,741 |  | 168,298 |  |  | 164,474 |  |  | 357,039 |  |  | 269,882 |
| Operating margin as a percent of revenue |  | 15.3\% |  | 14.6\% |  |  | 14.7\% |  |  | 15.0\% |  |  | 12.7\% |
| Other expense, net |  | (9,799 |  | (5,648 | ) |  | (3,837 | ) |  | $(15,447$ | ) |  | (18,099 |
| Income before income taxes |  | 178,942 |  | 162,650 |  |  | 160,637 |  |  | 341,592 |  |  | 251,783 |
| Income tax expense |  | 2,002 |  | 21,569 |  |  | 11,645 |  |  | 23,571 |  |  | 17,285 |
| Net income | \$ | 176,940 | \$ | 141,081 |  | \$ | 148,992 |  | \$ | 318,021 |  | \$ | 234,498 |

Net income per share:


CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)

|  | December 28, |  | September 28, |  | June 29, |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 2014 |  | 2014 |  | 2014 |  |
|  | (unaudited) |  | (unaudited) |  | (1) |  |
| ASSETS |  |  |  |  |  |  |
| Cash and cash equivalents | \$ | 981,275 | \$ | 1,293,678 | \$ | 1,452,677 |
| Short-term investments |  | 1,902,402 |  | 1,593,668 |  | 1,612,967 |
| Accounts receivable, net |  | 944,014 |  | 864,403 |  | 800,616 |
| Inventories |  | 913,390 |  | 815,612 |  | 740,503 |
| Other current assets |  | 173,731 |  | 123,615 |  | 176,899 |
| Total current assets |  | 4,914,812 |  | 4,690,976 |  | 4,783,662 |
| Property and equipment, net |  | 585,372 |  | 555,658 |  | 543,496 |
| Restricted cash and investments |  | 155,455 |  | 149,483 |  | 146,492 |
| Goodwill and intangible assets |  | 2,282,006 |  | 2,322,153 |  | 2,360,303 |
| Other assets |  | 173,044 |  | 175,558 |  | 159,353 |
| Total assets | \$ | 8,110,689 | \$ | 7,893,828 | \$ | 7,993,306 |
| LIABILITIES AND STOCKHOLDERS' EQUITY |  |  |  |  |  |  |
| Current liabilities | \$ | 1,708,656 | \$ | 1,599,625 | \$ | 1,582,001 |
| Long-term debt, convertible notes, and capital leases | \$ | 830,880 | \$ | 824,269 | \$ | 817,202 |
| Income taxes payable |  | 205,535 |  | 217,118 |  | 258,357 |
| Other long-term liabilities |  | 183,678 |  | 179,711 |  | 122,662 |
| Total liabilities |  | 2,928,749 |  | 2,820,723 |  | 2,780,222 |
| Senior convertible notes |  | 181,505 |  | 182,432 |  | 183,349 |
| Stockholders' equity ${ }^{(2)}$ |  | 5,000,435 |  | 4,890,673 |  | 5,029,735 |
| Total liabilities and stockholders' equity | \$ | 8,110,689 | \$ | 7,893,828 | \$ | 7,993,306 |

(1) Derived from audited financial statements
(2) Common shares issued and outstanding were 159,294 shares as of December 28, 2014, 159,384 shares as of September 28, 2014 and 162,350 shares as of June 29, 2014.

LAM RESEARCH CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)

| CASH FLOWS FROM OPERATING ACTIVITIES: |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Net income | \$ | 176,940 |  | \$ | 141,081 |  | \$ | 148,992 |  | \$ | 318,021 |  |
| Adjustments to reconcile net income to net cash provided by operating activities: |  |  |  |  |  |  |  |  |  |  |  |  |
| Depreciation and amortization |  | 69,536 |  |  | 67,885 |  |  | 73,552 |  |  | 137,421 |  |
| Deferred income taxes |  | 3,320 |  |  | 3,186 |  |  | 12,457 |  |  | 6,506 |  |
| Impairment of long-lived asset |  | - |  |  | - |  |  | 628 |  |  | - |  |
| Equity-based compensation expense |  | 30,632 |  |  | 32,040 |  |  | 23,046 |  |  | 62,672 |  |
| Income tax benefit on equity-based compensation plans |  | 1,141 |  |  | 9,861 |  |  | - |  |  | 11,002 |  |
| Excess tax benefit on equity-based compensation plans |  | (599 | ) |  | (10,404 | ) |  | - |  |  | (11,003 | ) |
| Amortization of convertible note discount |  | 8,609 |  |  | 8,509 |  |  | 8,217 |  |  | 17,118 |  |
| Gain on sale of business |  | - |  |  | (7,431 | ) |  | - |  |  | (7,431 | ) |
| Other, net |  | 1,607 |  |  | 5,526 |  |  | (2,428 | ) |  | 7,133 |  |
| Changes in operating assets and liabilities: |  | (129,947 | ) |  | (109,092 | ) |  | (135,441 | ) |  | (239,039 | ) |
| Net cash provided by operating activities |  | 161,239 |  |  | 141,161 |  |  | 129,023 |  |  | 302,400 |  |
| CASH FLOWS FROM INVESTING ACTIVITIES: |  |  |  |  |  |  |  |  |  |  |  |  |
| Capital expenditures and intangible assets |  | (61,363 | ) |  | (41,871 | ) |  | (38,323 | ) |  | (103,234 | ) |
| Cash paid for business acquisition |  | - |  |  | (1,137 | ) |  | (18,388 | ) |  | (1,137 | ) |
| Net sales/maturities (purchases) of available-for-sale securities |  | (321,590 | ) |  | 9,645 |  |  | (88,754 | ) |  | (311,945 | ) |
| Repayment of notes receivable |  | 3,978 |  |  | - |  |  | 10,000 |  |  | 3,978 |  |
| Proceeds from sale of business, net |  | - |  |  | 41,212 |  |  | - |  |  | 41,212 |  |
| Proceeds from sale of assets |  | - |  |  | - |  |  | 21,635 |  |  | - |  |
| Transfer of restricted cash and investments |  | 100 |  |  | 22 |  |  | - |  |  | 122 |  |
| Net cash (used for) provided by investing activities |  | (378,875 | ) |  | 7,871 |  |  | (113,830 | ) |  | (371,004 | ) |

CASH FLOWS FROM
FINANCING ACTIVITIES:

| Principal payments on long-term debt and capital lease obligations |  | (674 | ) |  | (107 | ) |  | (719 | ) |  | (781 | ) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Excess tax benefit on equity-based compensation plans |  | 599 |  |  | 10,404 |  |  | - |  |  | 11,003 |  |
| Treasury stock purchases |  | (65,536 | ) |  | (308,422 | ) |  | (47,910 | ) |  | (373,958 | ) |
| Dividends paid |  | (29,381 | ) |  | (29,240 | ) |  | - |  |  | (58,621 | ) |
| Reissuances of treasury stock related to employee stock purchase plan |  | - |  |  | 16,919 |  |  | (35 | ) |  | 16,919 |  |
| Proceeds from issuance of common stock |  | 4,223 |  |  | 4,609 |  |  | 8,449 |  |  | 8,832 |  |
| Net cash used for financing activities |  | (90,769 | ) |  | (305,837 | ) |  | (40,215 | ) |  | (396,606 | ) |
| Effect of exchange rate changes on cash |  | (3,998 | ) |  | (2,194 | ) |  | 1,393 |  |  | (6,192 | ) |
| Net decrease in cash and cash equivalents |  | (312,403 | ) |  | (158,999 | ) |  | (23,629 | ) |  | (471,402 | ) |
| Cash and cash equivalents at beginning of period |  | 1,293,678 |  |  | 1,452,677 |  |  | 1,156,184 |  |  | 1,452,677 |  |
| Cash and cash equivalents at end of period | \$ | 981,275 |  | \$ | 1,293,678 |  | \$ | 1,132,555 |  | \$ | 981,275 |  |

## Non-GAAP Financial Summary

(in thousands, except percentages and per share data)
(unaudited)

|  | Three Months Ended |  | Three Months Ended |  |
| :---: | :---: | :---: | :---: | :---: |
|  | December 28, |  | September 28, |  |
|  | 2014 |  | 2014 |  |
| Revenue | \$ | 1,232,241 | \$ | 1,152,368 |
| Gross margin | \$ | 560,044 | \$ | 528,032 |
| Gross margin as percentage of revenue |  | 45.4\% |  | 45.8\% |
| Operating expenses | \$ | 330,213 | \$ | 321,158 |
| Operating income | \$ | 229,831 | \$ | 206,874 |
| Operating margin as a percentage of revenue |  | 18.7\% |  | 18.0\% |
| Net income | \$ | 207,631 | \$ | 167,671 |
| Net income per diluted share | \$ | 1.19 | \$ | 0.96 |
| Shares used in per share calculation -- diluted |  | 174,316 |  | 175,433 |

Reconciliation of U.S. GAAP Net Income to Non-GAAP Net Income and U.S. GAAP number of dilutive shares to Non-GAAP number of dilutive shares
(in thousands, except share and per share data)
(unaudited)

|  | Three Months Ended |  |  | Three Months Ended |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | December 28, |  |  | September 28, |  |  |
|  | 2014 |  |  | 2014 |  |  |
| U.S. GAAP net income | \$ | 176,940 |  | \$ | 141,081 |  |
| Pre-tax non-GAAP items: |  |  |  |  |  |  |
| Amortization related to intangible assets acquired in Novellus transaction -- cost of goods sold |  | 21,286 |  |  | 20,893 |  |
| Costs associated with rationalization of certain product configurations -- cost of goods sold |  | - |  |  | 1,600 |  |
| Acquisition-related inventory fair value impact -- cost of goods sold |  | 2,101 |  |  | - |  |
| Amortization related to intangible assets acquired in Novellus transaction -- operating expenses |  | 16,083 |  |  | 16,083 |  |
| Restructuring charges - operating expenses |  | 1,620 |  |  | - |  |
| Amortization of convertible note discount, Lam notes -- other expense, net |  | 7,682 |  |  | 7,593 |  |
| Amortization of convertible note discount, Novellus assumed notes -- other expense, net |  | 927 |  |  | 911 |  |
| Net gain associated with disposition of a business -- other expense, net |  | - |  |  | (4,331 | ) |
| Net tax (benefit) expense on non-GAAP items |  | (7,914 | ) |  | $(13,348$ | ) |
| Net tax benefit on valuation allowance adjustment |  | - |  |  | (2,811 | ) |
| Net tax benefit on reinstatement of research and development credit |  | (11,094 | ) |  | - |  |
| Non-GAAP net income | \$ | 207,631 |  | \$ | 167,671 |  |
| Non-GAAP net income per diluted share | \$ | 1.19 |  | \$ | 0.96 |  |
| U.S. GAAP number of shares used for diluted per share calculation |  | 177,046 |  |  | 177,118 |  |
| Effect of convertible note hedge |  | (2,730 | ) |  | (1,685 | ) |
| Non-GAAP number of shares used for diluted per share calculation |  | 174,316 |  |  | 175,433 |  |

Reconciliation of U.S. GAAP Gross Margin, Operating Expenses and Operating Income to Non-GAAP Gross Margin, Operating Expenses and Operating Income (in thousands, except percentages)
(unaudited)

|  | Three Months Ended | Three Months Ended |
| :---: | :---: | :---: |
|  | December 28, | September 28, |
|  | 2014 | 2014 |
| U.S. GAAP gross margin | \$ 536,657 | \$ 505,539 |
| Pre-tax non-GAAP items: |  |  |
| Amortization related to intangible assets acquired in Novellus transaction -- cost of goods sold | 21,286 | 20,893 |
| Costs associated with rationalization of certain product | - | 1,600 |


| Acquisition-related inventory fair value impact -- cost of goods sold | 2,101 |  | - |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Non-GAAP gross margin | \$ | 560,044 | \$ | 528,032 |  |
| U.S. GAAP gross margin as a percentage of revenue |  | 43.6\% |  | 43.9\% |  |
| Non-GAAP gross margin as a percentage of revenue |  | 45.4\% |  | 45.8\% |  |
| U.S. GAAP operating expenses | \$ | 347,916 | \$ | 337,241 |  |
| Pre-tax non-GAAP items: |  |  |  |  |  |
| Amortization related to intangible assets acquired in Novellus transaction - operating expenses |  | (16,083 |  | (16,083 | ) |
| Restructuring charges -- operating expenses |  | (1,620 |  | - |  |
| Non-GAAP operating expenses | \$ | 330,213 | \$ | 321,158 |  |
| Non-GAAP operating income | \$ | 229,831 | \$ | 206,874 |  |
| Non-GAAP operating margin as a percent of revenue |  | 18.7\% |  | 18.0\% |  |

Lam Research Corporation Contact:
Audrey Charles
Investor Relations
Phone: 510-572-1615
E-mail: audrey.charles@lamresearch.com
Source: Lam Research Corporation

News Provided by Acquire Media
https://newsroom.lamresearch.com/2015-01-28-Lam-Research-Corporation-Reports-Financial-Results-for-the-Quarter-Ended-December-28,-2014

